{"meshTags":["Disease Progression","Humans","Male","Neoplasm Staging","Orchiectomy","Prognosis","Prostatic Neoplasms"],"meshMinor":["Disease Progression","Humans","Male","Neoplasm Staging","Orchiectomy","Prognosis","Prostatic Neoplasms"],"organisms":["6755","6755","6755","9606"],"publicationTypes":["Journal Article","Practice Guideline","Research Support, Non-U.S. Gov\u0027t"],"abstract":"The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel\u0027s most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-na√Øve disease. ","title":"Prostate Cancer, Version 1.2016.","pubmedId":"26733552"}